Associate Sponsor

Enzyvant Therapeutics is a biopharma company focused on developing transformative therapies for rare diseases with high unmet needs.  In 2018, Enzyvant anticipates filing a BLA for RVT-802 for the treatment of complete DiGeorge Syndrome.  Enzyvant also plans to initiate a clinical study of RVT-801 for the treatment of Farber Disease.  Enzyvant is seeking additional development stage projects through in-licensing or partnership, and will continue to deliver on its commitment to providing innovative therapies for patients and families affected by rare diseases.